This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neuronal ceroid lipofuscinosisNeuronal Ceroid Lipofuscinosis (NCL / Batten Disease)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E75.4 | Special Copayment Reduction: V117 (5 years)
B. SynonymsSpielmeyer-Vogt disease, Kufs disease, Batten disease, Jansky-Bielschowsky disease (all synonyms/subtypes of E75.4)
C. Adult onsetLow likelihood of first onset in adulthood — most cases begin in childhood to adolescence, but the Kufs type (adult NCL, CLN4, CLN6, etc.) can appear in adulthood
1. HistoryAbout 130 years of research history, from early case descriptions by European physicians in the late 19th century to the discovery of the CLN gene family
2. CausesMutations in the CLN1–CLN14 genes cause lysosomal dysfunction → accumulation of ceroid-lipofuscin → neuronal death
3. GeneticsMostly autosomal recessive inheritance; only CLN4 (ANCL) is autosomal dominant; 14 CLN genes, each encoding a different protein
4. Epidemiology1–9 per 100,000 births worldwide; high prevalence in some countries such as Finland; CLN3 is the most common subtype
5. PathophysiologyLysosomal enzyme deficiency or membrane protein dysfunction → accumulation of autofluorescent ceroid-lipofuscin → activation of neuroinflammation and apoptosis pathways
6. SymptomsVision loss, progressive cognitive decline, epileptic seizures, movement disorders; age of onset differs by subtype
7. SignsRetinal degeneration on funduscopy, EEG abnormalities (occipital spikes), brain atrophy on MRI, characteristic electron microscopic findings on skin or rectal biopsy
8. ScreeningEnzyme activity measurement (CLN1: PPT1, CLN2: TPP1); newborn dried blood spot testing at the research stage
9. DiagnosisMultifaceted approach including gene panel/whole-exome analysis, electron microscopic biopsy, enzyme activity testing, MRI, and EEG
10. TreatmentCLN2: intraventricular cerliponase alfa (Brineura®) FDA approved (2017); symptom control and gene therapy clinical trials under way
11. PrognosisDiffers by subtype; most die within years to decades from progressive neurodegeneration; progression can be delayed with ERT in CLN2
12. PreventionCarrier testing, prenatal genetic diagnosis, preimplantation genetic testing (PGT); genetic counseling of affected families is essential
13. ReferencesMole SE et al. (2019) Biochim Biophys Acta Mol Basis Dis and 9 other papers

1. History

Clinical descriptions of neuronal ceroid lipofuscinosis (NCL) date back to the late 19th century. In 1826 the Norwegian physician Christian Stengel reported the first related cases, and in 1903 Heinrich Vogt in Germany systematically described a pediatric neurodegenerative disease characterized by visual impairment, epilepsy, and dementia. Subsequently, Friedrich Batten (1903), Max Spielmeyer (1905), Karl Vogt (1905), and others described the juvenile subtype in detail, and the compound name 'Spielmeyer-Vogt-Batten disease' was used. In 1969 Zeman and Dyken unified this group of diseases under the name 'neuronal ceroid lipofuscinosis' on the basis of the common pathological finding of intracellular accumulation of autofluorescent lipopigment. With advances in molecular genetics, the CLN1 (PPT1) gene was first identified in 1995, and CLN2 (TPP1, 1997), CLN3 (1995), and CLN5–CLN14 were subsequently identified in turn. To date, 14 CLN genes have been identified, and 13 or more subtypes are defined by mutations in each gene. In 2017, cerliponase alfa (Brineura®) received FDA approval for CLN2 disease, achieving the first disease-modifying treatment in the history of NCL. In Korea, it is registered under Special Copayment Reduction code V117 (ICD-10: E75.4), and patients can receive support for medical expenses.

2. Causes

The cause of NCL is mutations in the CLN gene family (CLN1–CLN14). Each gene encodes an intralysosomal enzyme or membrane protein, and when mutations occur, lysosomal function is impaired and an autofluorescent lipopigment protein called ceroid-lipofuscin accumulates abnormally in neurons. The causative genes and deficient proteins of the main subtypes are as follows.

SubtypeGeneDeficient proteinAge of onset
CLN1 (infantile NCL)CLN1/PPT1Palmitoyl-protein thioesterase 16–24 months of age
CLN2 (late infantile NCL, Jansky-Bielschowsky)CLN2/TPP1Tripeptidyl-peptidase 12–4 years
CLN3 (juvenile NCL, Spielmeyer-Vogt/Batten)CLN3CLN3 membrane protein (function not established)4–10 years
CLN4 (adult NCL, Kufs disease type A)DNAJC5CSPα (cysteine-string protein)Adulthood
CLN5CLN5CLN5 protein (soluble lysosomal protein)Childhood
CLN6CLN6CLN6 membrane proteinChildhood to adulthood
CLN7MFSD8Transmembrane proteinChildhood
CLN8CLN8CLN8 membrane proteinChildhood
CLN10 (congenital NCL)CTSDCathepsin DAround birth

CLN1, CLN2, and CLN10 encode soluble lysosomal enzymes, and deficiency of these enzymes directly causes substrate accumulation. In contrast, CLN3 and CLN5–CLN8 are lysosomal membrane proteins, and the exact molecular mechanisms have not yet been fully elucidated. The main accumulated substrates differ by subtype: in CLN1, saposins A and D, and in CLN2 and CLN3, subunit c of mitochondrial ATP synthase are the main accumulated materials.

3. Genetics

NCL is mostly inherited in an autosomal recessive manner. However, CLN4A (DNAJC5 mutation, Kufs disease type A) is the only subtype showing an autosomal dominant inheritance pattern. To date, 14 gene loci corresponding to CLN1–CLN14 have been identified, and hundreds of pathogenic mutant variants (missense, nonsense, splicing, deletion/insertion, etc.) have been reported in each gene. In the case of the CLN3 gene, about 80–85% of all patients are homozygous for a 1 kb deletion spanning exons 7–8 (c.461-280_677+382del), which is the founder mutation of juvenile NCL. CLN1 mutations are observed at particularly high frequency in the Finnish population (c.364A>T, p.Arg122Trp). Common mutations in CLN2 disease include c.509-1G>C and c.1234G>C. Genotype–phenotype correlations are well established in some subtypes (e.g., CLN1), but in other subtypes even the same mutation can have variable clinical phenotypes. Molecular diagnosis by gene panel testing or whole-exome sequencing (WES) is recommended. Both carrier parents are mostly asymptomatic, and each child has a 25% chance of being affected.

4. General epidemiology

NCL is the most common group of pediatric neurodegenerative lysosomal storage disorders, with a reported incidence of about 1–9 per 100,000 births worldwide. There are considerable differences in prevalence among countries and populations. In Finland, the incidence of CLN1 (infantile NCL) is particularly high at about 1.3 per 100,000 births, which is understood as part of the Finnish disease heritage. CLN3 (juvenile NCL) is the most common subtype worldwide, reported at 0.5–0.7 per 100,000 births in Northern Europe. In the United States, CLN2 is diagnosed relatively commonly, and hundreds of patients are registered worldwide. There is no difference in incidence by sex, and founder effects of specific CLN genes are sometimes observed in particular regions or ethnic groups. Accurate prevalence statistics for Korea are limited, but data are gradually accumulating through the rare disease registry program. The overall prevalence of NCL is estimated at about 0.5–2 per 100,000 population.

5. Pathophysiology

The core pathophysiology of NCL is abnormal intracellular accumulation of ceroid-lipofuscin due to lysosomal enzyme deficiency or membrane protein dysfunction. This autofluorescent lipopigment consists of denatured lipid–protein complexes and accumulates continuously because of impaired enzymatic degradation within lysosomes.

In CLN1 (PPT1 deficiency), palmitoyl-protein thioesterase 1 is responsible for removing lipids from palmitoylated proteins, and when this enzyme is deficient, S-acylated proteins and their degradation products accumulate in lysosomes. In CLN2 (TPP1 deficiency), deficiency of tripeptidyl-peptidase 1 prevents cleavage of N-terminal tripeptides from various proteins, so that in particular subunit c of mitochondrial ATP synthase accumulates in lysosomes.

The exact function of the CLN3 membrane protein has not yet been fully elucidated, but it has been proposed to be involved in several mechanisms, including regulation of lysosomal pH, arginine transport, and regulation of autophagy. Accumulation of ceroid-lipofuscin causes overall impairment of the lysosome–autophagy pathway, which leads to mitochondrial dysfunction, endoplasmic reticulum stress, and oxidative stress. This is followed by neuroinflammation (activation of microglia and astrocytes), increased cytokine secretion, and ultimately neuronal death (apoptosis, necroptosis). Retinal photoreceptors and cerebral cortical neurons are particularly vulnerable, so vision loss and cognitive decline appear early.

6. Symptoms

The clinical symptoms of NCL vary with subtype (CLN genotype) and age of onset, but progressive neurodegeneration is observed in all subtypes. The main symptoms are as follows.

Infantile NCL (CLN1, PPT1 deficiency)

Begins with developmental delay at 6–24 months of age and is characterized by rapid neurodegeneration, myoclonus, vision loss, and microcephaly. Progresses to severe encephalopathy within 2–3 years of life.

Late infantile NCL (CLN2, TPP1 deficiency)

Presents at 2–4 years with delayed language development or aphasia, followed within months by drug-resistant seizures, motor regression, and vision loss. Between ages 4 and 7, occipital spike waves after low-frequency photic stimulation characteristically appear on EEG, an important clinical marker when CLN2 is suspected.

Juvenile NCL (CLN3, Spielmeyer-Vogt/Batten disease)

Begins with visual impairment (retinal degeneration) at 4–10 years, and in most school-age children decreased vision is the first symptom. Cognitive decline, behavioral problems, parkinsonism-like movement disorders, and epilepsy follow. The rate of progression is slower than in CLN1 and CLN2, and some survive into their 20s–30s.

Adult NCL (Kufs disease, CLN4, CLN6, etc.)

Appears after age 30, with progressive dementia, cerebellar ataxia, epilepsy, and extrapyramidal symptoms as the main clinical features. Vision loss is mostly absent or mild, which distinguishes it from the pediatric forms. It is subdivided into CLN4A (autosomal dominant) and CLN4B (autosomal recessive, Parry disease).

Symptoms commonly observed in all subtypes are progressive cognitive decline, epileptic seizures, and movement disorders, ultimately reaching a vegetative state.

7. Signs

Clinical signs important for the diagnosis of NCL are observed from multiple perspectives as follows.

Ophthalmologic findings

In CLN2 and CLN3, early retinal pigmentary degeneration (bull's eye maculopathy) is observed on funduscopy, and electroretinography (ERG) shows absent or severely reduced waveforms. Vision loss is most marked and earliest in CLN3, and is also observed early in the disease in CLN1 and CLN2. In the adult form (Kufs disease), retinal findings are absent or mild.

Electroencephalogram (EEG) findings

In CLN2, occipital spike–slow wave complexes after low-frequency (1–2 Hz) photic stimulation are observed in more than 90%, a CLN2-specific finding that is very useful for diagnosis. In CLN3, generalized slowing and epileptiform discharge patterns appear.

Brain MRI findings

Cerebral and cerebellar atrophy, white matter changes, and T2 hyperintensity are observed in various subtypes. T2 hypointensity of the basal ganglia and thalamus has been reported in CLN3. MRI may be normal early in the disease, and cortical and subcortical atrophy become marked as it progresses.

Electron microscopic biopsy findings

On electron microscopy of skin, rectal mucosa, or leukocytes, characteristic inclusion morphologies are observed for each subtype. Granular osmiophilic deposits (GROD) appear in CLN1, curvilinear bodies in CLN2, and fingerprint profiles and mixed-type bodies in CLN3.

Other clinical signs

Myoclonus, abnormal movements, microcephaly, changes in muscle tone, dysphagia, and others appear with progression. The terminal stage is characterized by limb contractures, a bedridden state, and nutritional disorders.

8. Screening

Standardized population-based newborn screening for NCL has not yet been established, but various biochemical and molecular screening methods are being developed at the research stage.

Enzyme activity screening

For the CLN1 and CLN2 subtypes, methods to measure lysosomal enzyme activity (PPT1 and TPP1, respectively) in dried blood spots (DBS) by fluorogenic substrate assays are being studied. Because this method can be added to existing multiplex enzyme assay platforms, it is technically possible to perform it simultaneously with screening for other metabolic diseases such as phenylketonuria.

Screening of high-risk groups

NCL should be considered first in children with clinically unexplained progressive neurodegeneration, drug-resistant epilepsy, and vision loss. In particular, when decreased vision progresses together with seizures in children aged 2–7, screening tests for CLN2 and CLN3 are performed early.

Molecular genetic screening

When there is a family history, or in certain high-risk populations (Finland, Eastern Europe, etc.), targeted genetic screening for the most common CLN mutations is performed. The founder deletion mutation of CLN3 (1 kb del) can be rapidly confirmed by PCR-based testing.

Testing of the EEG response to low-frequency photic stimulation is recommended as a noninvasive screening marker for CLN2, and early performance of this test is advised in children under 5 years of age with new-onset seizures.

9. Diagnosis

Confirmation of NCL is achieved by integrating molecular genetic testing, biochemical enzyme testing, pathological examination (electron microscopy), and clinical and neuroimaging findings.

Molecular genetic diagnosis

Next-generation sequencing (NGS)-based NCL gene panel testing or whole-exome sequencing (WES) is recommended as the first-line diagnostic tool. Panel testing including the CLN1–CLN14 genes can analyze most subtypes simultaneously, with a diagnostic yield of 70–90%. For unidentified variants, whole-genome sequencing (WGS) may additionally be performed.

Enzyme activity testing

For CLN1 (PPT1) and CLN2 (TPP1), enzyme activity can be measured directly in leukocytes, dried blood spots, or fibroblasts, enabling rapid biochemical diagnosis of infantile and late infantile NCL. Activity below 10–20% of normal controls indicates enzyme deficiency.

Electron microscopic biopsy

Electron microscopy of skin or rectal mucosal tissue identifies the characteristic lysosomal inclusions of each subtype (GROD, curvilinear bodies, fingerprint profiles). It is useful when molecular diagnosis is difficult, and a negative result does not completely exclude NCL.

Imaging and electrophysiological testing

Brain MRI (particularly T2/FLAIR) identifies cerebral atrophy and white matter changes, and EEG evaluates the CLN2-specific occipital spike response. Electroretinography (ERG) and visual evoked potential (VEP) testing objectify the extent of retinal involvement.

Biomarkers

Neurofilament light chain (NfL) in cerebrospinal fluid or plasma can be used as a nonspecific biomarker to monitor the progression of neurodegeneration in NCL. In addition, measurement of plasma PPT1 and TPP1 activity is used for diagnosis of CLN1 and CLN2 and for monitoring treatment effects.

10. Treatment

For most subtypes of NCL there is still no curative treatment, but an FDA-approved enzyme replacement therapy exists for CLN2 disease, and numerous clinical trials are under way.

CLN2: Cerliponase alfa (Brineura®)

The first NCL treatment, approved by the FDA in April 2017, in which recombinant human tripeptidyl-peptidase 1 (rhTPP1) is infused directly into the brain parenchyma through an intraventricular catheter every 2 weeks. Each dose is 300 mg, infused into the cerebrospinal fluid over about 4 hours. In a phase 3 clinical study (NCT01907087), the decline in CLN2 motor–language scores was significantly delayed in the treatment group compared with the placebo group. Long-term follow-up studies have also confirmed that the treatment effect is maintained for several years.

Symptomatic treatment

For seizure control, antiepileptic drugs such as valproic acid, levetiracetam, and clonazepam are used. Clonazepam and piracetam are effective for myoclonus. Carbamazepine and phenytoin require caution because they may worsen myoclonus. When dysphagia has progressed, gastrostomy tube (PEG) placement is needed, and physical therapy and orthoses help with spasticity and contractures.

Gene therapy (clinical trial stage)

A phase 1/2 clinical trial of intraventricular gene therapy using an AAV9 vector for CLN3 disease is under way, and a clinical trial of intrathecal AAV9-CLN6 for CLN6 is also in progress. AAV9 gene therapy for CLN1 is also in development.

Hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation has been attempted in some cases of CLN1, but its effect in halting neurological progression is limited, and it is not currently recommended as standard treatment.

11. Prognosis

The prognosis of NCL differs considerably by subtype, but overall the prognosis is poor. Disease progression is irreversible, and all subtypes lead to death.

Infantile NCL (CLN1) has the most rapid course, with most patients dying before age 5–8. Late infantile NCL (CLN2) leads to death at age 6–12 without treatment, but cerliponase alfa treatment can significantly reduce the rate of functional decline and is expected to prolong survival. Juvenile NCL (CLN3) shows relatively slow progression, and some patients survive into their teens to 30s, but independent living into adulthood is mostly impossible. Adult NCL (Kufs disease) shows a progressive course over decades after onset, and the prognosis varies with age of onset.

The main causes of death are status epilepticus, aspiration pneumonia, and complications of malnutrition. Symptom management and maintenance of quality of life through a multidisciplinary team (neurology, ophthalmology, rehabilitation medicine, nutrition, palliative care team) are important. Plasma and cerebrospinal fluid NfL are used as biomarkers of disease progression and help in prognostic follow-up.

12. Prevention

Because NCL is a hereditary disease, there is currently no primary prevention, but the birth of affected children can be prevented through genetic counseling and assisted reproductive technologies.

Genetic counseling

Genetic counseling must be provided to families with a patient with NCL. In most subtypes, which are autosomal recessive, the parents are carriers, and each pregnancy has a 25% chance of an affected child. In autosomal dominant CLN4A, it is inherited by the children of an affected person with a 50% probability.

Carrier testing

Molecular genetic carrier testing can identify at-risk members within the family. Testing of the patient's siblings, parents, and spouse is particularly recommended. In high-risk ethnic groups (Finns, Eastern European Jews, etc.), population-based carrier screening may be considered.

Prenatal diagnosis and preimplantation genetic testing

When the parents' pathogenic variants have been identified, prenatal genetic diagnosis by chorionic villus sampling (CVS) or amniocentesis is possible in subsequent pregnancies. In addition, preimplantation genetic testing (PGT-M) performed together with in vitro fertilization can prevent the birth of affected children by selectively transferring unaffected embryos.

Newborn screening and early diagnosis

Because disease progression in some NCL subtypes, including CLN2, can be delayed by early diagnosis and treatment, research on including them in newborn screening programs is under way. Early molecular diagnosis in suspected cases provides an opportunity to start treatment before or early after symptom onset.

13. References

  1. Mole SE, Anderson G, Band HA, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107-116. PMID: 30470609. DOI: 10.1016/S1474-4422(18)30368-5
  2. Specchio N, Bellusci M, Pietrafusa N, et al. Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease. Expert Opin Orphan Drugs. 2019;7(7-8):325-333. DOI: 10.1080/21678707.2019.1651764
  3. Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33(4):315-325. PMID: 30820891. DOI: 10.1007/s40263-019-00620-8
  4. Sondhi D, Kaminsky SM, Hackett NR, et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 AAV expressing CLN2. Sci Transl Med. 2020;12(572):eabb0582. PMID: 33239384. DOI: 10.1126/scitranslmed.abb0582
  5. Schulz A, Ajayi T, Specchio N, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018;378(20):1898-1907. PMID: 29768152. DOI: 10.1056/NEJMoa1710176
  6. Geraets RD, Koh SY, Hastings ML, Bhattacharyya S. Moving towards effective therapeutic strategies for neuronal ceroid lipofuscinosis. Orphanet J Rare Dis. 2016;11(1):40. PMID: 27067907. DOI: 10.1186/s13023-016-0414-2
  7. Radke J, Stenzel W, Goebel HH. Human NCL Neuropathology. Biochim Biophys Acta. 2015;1852(10 Pt B):2262-2266. PMID: 25882387. DOI: 10.1016/j.bbadis.2015.04.007
  8. Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(S2):73-88. PMID: 27723541. DOI: 10.1684/epd.2016.0845
  9. Topçu M, Tan H. Practical approach to a patient with progressive encephalopathy with emphasis on neuronal ceroid lipofuscinoses. Semin Pediatr Neurol. 2006;13(1):14-23. PMID: 16818174. DOI: 10.1016/j.spen.2006.01.003
  10. Mole SE, Williams RE, Goebel HH (eds). The Neuronal Ceroid Lipofuscinoses (Batten Disease). 2nd ed. Oxford University Press; 2011. ISBN: 9780199590353